The application of AI technology in new drug development spans several critical stages, from compound synthesis to drug repurposing.

In 2023, the global market for AAV (Adeno-associated virus) therapies reached $1.5 billion, with projections suggesting growth to $22.3 billion by 2029.

AI-driven technological innovation not only enhances the targeting precision of siRNA but also paves new pathways for future gene therapies.

Recently,the Center for Drug Evaluation of the NMPA announced the acceptance of the investigational new drug (IND) application for Novartis's PIT565 injection.

Tiziana Life Sciences announced that its intranasally administered anti-CD3 monoclonal antibody, foralumab.

Recently, Vivoryon Therapeutics presented new analysis data for varoglutamstat at the 2024 American Society of Nephrology (ASN) meeting.

Novartis will acquire a clinical-stage molecular glue named MRT-6160, providing Monte Rosa with an upfront payment of $150 million.

According to statistical data, the miRNA drug market was estimated at approximately $160.5 million in 2017, with an expected compound annual growth rate (CAGR) of 18.6%.

As a cutting-edge therapeutic approach, antisense oligonucleotide drugs precisely target the mRNA or pre-mRNA of disease-causing genes.

Otsuka Pharmaceutical announced positive top-line interim data from the phase III clinical trial of sibeprenlimab for treating adults with IgA nephropathy.

Hope Medicine (HopeMed) announced positive interim results from a Phase 2 study of HMI-115 in women with moderate to severe endometriosis-associated pain.

Tonix Pharmaceuticals announced that it has submitted a New Drug Application (NDA) to the U.S. FDA for TNX-102 SL (Cyclobenzaprine hydrochloride).